Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103161845> ?p ?o ?g. }
- W2103161845 endingPage "2334" @default.
- W2103161845 startingPage "2327" @default.
- W2103161845 abstract "No AccessJournal of UrologyInvestigative Urology1 Jun 2013The Role of c-FLIP in Cisplatin Resistance of Human Bladder Cancer Cells Sangchul Lee, Cheol Yong Yoon, Seok-Soo Byun, Eunsik Lee, and Sang Eun Lee Sangchul LeeSangchul Lee Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author , Cheol Yong YoonCheol Yong Yoon Department of Urology, Korea University Hospital, Seoul, Korea More articles by this author , Seok-Soo ByunSeok-Soo Byun Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author , Eunsik LeeEunsik Lee Seoul National University Hospital, Seoul, Korea More articles by this author , and Sang Eun LeeSang Eun Lee Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.01.003AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated the mechanisms underlying cisplatin resistance in human bladder cancer cells to provide novel molecular targets for the treatment of cisplatin resistant bladder cancer. Materials and Methods: The differential gene expression of cisplatin sensitive (T24) and resistant (T24R2) human bladder cancer cell lines was analyzed and validated by microarray and Western blot analysis. Changes in cisplatin sensitivity by c-FLIP knockdown and related mechanisms in T24R2 cells were assessed using the Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, Maryland) and Western blot. siRNA oligonucleotides that specifically target c-FLIP were prepared and siRNA transfection was done. Results: Microarray analysis revealed that the expression of 1,086 and 322 genes showed more than twofold and fourfold changes in the T24R2 and T24 cell lines, respectively. Especially genes involved in the c-FLIP related death receptor apoptosis pathway, including caspase 2 and 9, NF-kB, BID, c-FLIP, XIAP, and cIAP1 and 2, showed differential expression in the 2 cell lines. Western blot demonstrated complete cisplatin mediated suppression of c-FLIP expression in T24 cells but no change in c-FLIP expression was observed in T24R2 cells after cisplatin treatment in the same dose range. Suppression of c-FLIP expression in T24R2 cells by siRNA transfection rendered these cells significantly more sensitive to cisplatin treatment than untransfected T24R2 cells (p <0.05). Conclusions: Results reveal that c-FLIP has an important role in the cisplatin resistance of human bladder cancer cells and c-FLIP modulation may at least partially reverse cisplatin resistance in bladder cancer cells. References 1 : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005; 23: 4602. Google Scholar 2 : Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000; 18: 3068. Google Scholar 3 : First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol2011; 18: e25. Google Scholar 4 : Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol2001; 165: 67. Link, Google Scholar 5 : Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol2008; 13: 510. Google Scholar 6 : Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol2007; 18: 1359. Google Scholar 7 : Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol2009; 27: 4454. Google Scholar 8 : Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev2007; 33: 9. Google Scholar 9 : Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett2006; 237: 56. Google Scholar 10 : Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett2004; 212: 61. Google Scholar 11 : Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int2005; 95: 1086. Google Scholar 12 : Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer2002; 2: 277. Google Scholar 13 : Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol2010; 42: 210. Google Scholar 14 : The role of c-FLIP splice variants in urothelial tumours. Cell Death Dis2011; 2: e245. Google Scholar 15 : The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem2007; 282: 18800. Google Scholar 16 : Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther2005; 4: 2026. Google Scholar 17 : Mechanisms of resistance to cisplatin. Mutat Res2001; 478: 23. Google Scholar 18 : Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets2008; 8: 37. Google Scholar 19 : Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci U S A2004; 101: 6611. Google Scholar 20 : Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther2007; 6: 1544. Google Scholar 21 : c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene2006; 25: 838. Google Scholar 22 : Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem2005; 280: 19401. Google Scholar 23 : c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol2008; 76: 1694. Google Scholar 24 : c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology2004; 63: 1198. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAndersson K (2018) This Month in Investigative UrologyJournal of Urology, VOL. 189, NO. 6, (2015-2016), Online publication date: 1-Jun-2013. Volume 189Issue 6June 2013Page: 2327-2334 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordsdrug resistanceurinary bladdercisplatingene expressioncarcinomaMetricsAuthor Information Sangchul Lee Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author Cheol Yong Yoon Department of Urology, Korea University Hospital, Seoul, Korea More articles by this author Seok-Soo Byun Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author Eunsik Lee Seoul National University Hospital, Seoul, Korea More articles by this author Sang Eun Lee Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2103161845 created "2016-06-24" @default.
- W2103161845 creator A5019050469 @default.
- W2103161845 creator A5026337966 @default.
- W2103161845 creator A5035133412 @default.
- W2103161845 creator A5037434900 @default.
- W2103161845 creator A5047903672 @default.
- W2103161845 date "2013-06-01" @default.
- W2103161845 modified "2023-09-25" @default.
- W2103161845 title "The Role of c-FLIP in Cisplatin Resistance of Human Bladder Cancer Cells" @default.
- W2103161845 cites W1966023125 @default.
- W2103161845 cites W1973198032 @default.
- W2103161845 cites W1979174576 @default.
- W2103161845 cites W1979325887 @default.
- W2103161845 cites W2014966556 @default.
- W2103161845 cites W2018725927 @default.
- W2103161845 cites W2046670589 @default.
- W2103161845 cites W2049701654 @default.
- W2103161845 cites W2064862565 @default.
- W2103161845 cites W2077501853 @default.
- W2103161845 cites W2084390674 @default.
- W2103161845 cites W2096927220 @default.
- W2103161845 cites W2101562875 @default.
- W2103161845 cites W2102116016 @default.
- W2103161845 cites W2103257412 @default.
- W2103161845 cites W2105555467 @default.
- W2103161845 cites W2114859751 @default.
- W2103161845 cites W2116527823 @default.
- W2103161845 cites W2125988618 @default.
- W2103161845 cites W2134220063 @default.
- W2103161845 cites W2153906296 @default.
- W2103161845 cites W2154756022 @default.
- W2103161845 cites W2155200468 @default.
- W2103161845 cites W2168496310 @default.
- W2103161845 doi "https://doi.org/10.1016/j.juro.2013.01.003" @default.
- W2103161845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23313194" @default.
- W2103161845 hasPublicationYear "2013" @default.
- W2103161845 type Work @default.
- W2103161845 sameAs 2103161845 @default.
- W2103161845 citedByCount "24" @default.
- W2103161845 countsByYear W21031618452013 @default.
- W2103161845 countsByYear W21031618452014 @default.
- W2103161845 countsByYear W21031618452015 @default.
- W2103161845 countsByYear W21031618452016 @default.
- W2103161845 countsByYear W21031618452017 @default.
- W2103161845 countsByYear W21031618452018 @default.
- W2103161845 countsByYear W21031618452019 @default.
- W2103161845 countsByYear W21031618452020 @default.
- W2103161845 countsByYear W21031618452021 @default.
- W2103161845 countsByYear W21031618452023 @default.
- W2103161845 crossrefType "journal-article" @default.
- W2103161845 hasAuthorship W2103161845A5019050469 @default.
- W2103161845 hasAuthorship W2103161845A5026337966 @default.
- W2103161845 hasAuthorship W2103161845A5035133412 @default.
- W2103161845 hasAuthorship W2103161845A5037434900 @default.
- W2103161845 hasAuthorship W2103161845A5047903672 @default.
- W2103161845 hasConcept C121608353 @default.
- W2103161845 hasConcept C126322002 @default.
- W2103161845 hasConcept C143998085 @default.
- W2103161845 hasConcept C18903297 @default.
- W2103161845 hasConcept C190283241 @default.
- W2103161845 hasConcept C2776591724 @default.
- W2103161845 hasConcept C2776694085 @default.
- W2103161845 hasConcept C2778239845 @default.
- W2103161845 hasConcept C2780352672 @default.
- W2103161845 hasConcept C3020745361 @default.
- W2103161845 hasConcept C502942594 @default.
- W2103161845 hasConcept C54355233 @default.
- W2103161845 hasConcept C57473165 @default.
- W2103161845 hasConcept C71924100 @default.
- W2103161845 hasConcept C86803240 @default.
- W2103161845 hasConceptScore W2103161845C121608353 @default.
- W2103161845 hasConceptScore W2103161845C126322002 @default.
- W2103161845 hasConceptScore W2103161845C143998085 @default.
- W2103161845 hasConceptScore W2103161845C18903297 @default.
- W2103161845 hasConceptScore W2103161845C190283241 @default.
- W2103161845 hasConceptScore W2103161845C2776591724 @default.
- W2103161845 hasConceptScore W2103161845C2776694085 @default.
- W2103161845 hasConceptScore W2103161845C2778239845 @default.
- W2103161845 hasConceptScore W2103161845C2780352672 @default.
- W2103161845 hasConceptScore W2103161845C3020745361 @default.
- W2103161845 hasConceptScore W2103161845C502942594 @default.
- W2103161845 hasConceptScore W2103161845C54355233 @default.
- W2103161845 hasConceptScore W2103161845C57473165 @default.
- W2103161845 hasConceptScore W2103161845C71924100 @default.
- W2103161845 hasConceptScore W2103161845C86803240 @default.
- W2103161845 hasIssue "6" @default.
- W2103161845 hasLocation W21031618451 @default.
- W2103161845 hasLocation W21031618452 @default.
- W2103161845 hasOpenAccess W2103161845 @default.
- W2103161845 hasPrimaryLocation W21031618451 @default.
- W2103161845 hasRelatedWork W1984272130 @default.
- W2103161845 hasRelatedWork W2342346437 @default.
- W2103161845 hasRelatedWork W2598159573 @default.
- W2103161845 hasRelatedWork W2892336168 @default.
- W2103161845 hasRelatedWork W3087531285 @default.
- W2103161845 hasRelatedWork W4235080808 @default.
- W2103161845 hasRelatedWork W4235149650 @default.